Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis

Michael Haddadin, Adham Obedat, Farah Al-Bitar, Lori Maness, Krishna Gundabolu, Shyam Ajay Patel, Vijaya Raj Bhatt

Blood (2024) 144 (Supplement 1): 2125.

https://doi.org/10.1182/blood-2024-204507

Published: 2024

Journal Articles

Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State

Adam Kanack, Guillaume Roberge, Emily Mauch, Noah Splinter, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Krishna Gundabolu, Jon Coker, Mindy Kohlhagen, David Murray, Anand Pabmanabhan

Blood (2024) 144 (Supplement 1): 1227.

https://doi.org/10.1182/blood-2024-208364

Published: 2024

Journal Articles

Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT

Thuy T Koll, Megan Kerns, Tanya M. Wildes, Vijaya Raj Bhatt, Krishna Gundabolu, Lori Maness, Michael Haddadin, Marcia Free, Elizabeth R Lyden, Daniel L Murman, Alfred L Fisher

Blood (2024) 144 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2024-210392

Published: 2024

Journal Articles

Averting a terminal transplant cascade

Krishna Gundabolu, Vijaya Raj Bhatt

Blood (2024) 143 (12): 1059–1060.

https://doi.org/10.1182/blood.2023023199

Published: 2024

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Marina Y. Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, Abhishek Maiti, Krishna Gundabolu, Kyle Jensen, Jolie Schafer, Gu Mi, Agata Drewniak, Heidi Krenz, Rao Saleem, Giovanni Abbadessa, Naval Daver

Blood (2023) 142 (Supplement 1): 5972.

https://doi.org/10.1182/blood-2023-174030

Published: 2023

Journal Articles

Use of Geriatric Assessment and Genetic Profiling to Personalize Selection of Intensive Versus Low Intensity Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML): Final Results of a Phase II Trial

Vijaya Raj Bhatt, Christopher Wichman, Thuy T Koll, Alfred Fisher, Tanya M. Wildes, Michael Haddadin, Ann Berger, James Olen Armitage, Sarah A. Holstein, Lori Maness, Krishna Gundabolu

Blood (2023) 142 (Supplement 1): 4265.

https://doi.org/10.1182/blood-2023-178112

Published: 2023

Journal Articles

Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies

Adam J. Kanack, Curtis G. Jones, Bandana Singh, Rachel R. Leger, Noah P. Splinter, Nahla M. Heikal, Rajiv K. Pruthi, Dong Chen, Gemlyn George, Mouhamed Y. Abou-Ismail, Geoffrey D. Wool, Krishna Gundabolu, Anand Padmanabhan

Blood (2022) 140 (25): 2722–2729.

https://doi.org/10.1182/blood.2022017283

Published: 2022

Includes: Supplemental data

Journal Articles

Novel First-in-Class Drug ONC201 As a Post-Transplant Maintenance for AML and MDS: A Phase I Trial in Progress

Vijaya Raj Bhatt, Christopher Wichman, Alyssa C. Bouska, Lori Maness, Zaid S. Al-Kadhimi, Javeed Iqbal, James E. Talmadge, Krishna Gundabolu

Blood (2022) 140 (Supplement 1): 12918–12919.

https://doi.org/10.1182/blood-2022-156316

Published: 2022

Journal Articles

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial

Vijaya Raj Bhatt, Valerie K Shostrom, Ayman Saad, Betty K. Hamilton, Krishna Gundabolu, Lori Maness, Virender Kumar, Ram I Mahato, Lynette M. Smith, Taiga Nishihori, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 1379–1380.

https://doi.org/10.1182/blood-2022-156340

Published: 2022

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients’ Function and Health-Related Quality of Life Change with Treatment?

Vijaya Raj Bhatt, Christopher Wichman, Zaid S. Al-Kadhimi, Thuy T. Koll, Alfred L Fisher, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori Maness, Krishna Gundabolu

Blood (2022) 140 (Supplement 1): 8991–8992.

https://doi.org/10.1182/blood-2022-156310

Published: 2022

Journal Articles

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Naveen Pemmaraju, Krishna Gundabolu, Jack Snyder, Michael H Silverman, Geraldine Bardelli, Srdan Verstovsek, Gary J. Schiller

Blood (2022) 140 (Supplement 1): 6821–6822.

https://doi.org/10.1182/blood-2022-169852

Published: 2022

Journal Articles

Outcomes of Patients with Budd-Chiari Syndrome and Factors Predicting the Need for TIPS & Liver Transplantation - a Single-Center Long-Term Experience

Anusha Gopalam, Valerie K Shostrom, Vijaya R. Bhatt, Alex Nester, Laxmi Narayana Buddharaju, Marco Olivera, Krishna Gundabolu

Blood (2021) 138 (Supplement 1): 2123.

https://doi.org/10.1182/blood-2021-148852

Published: 2021

Journal Articles

Poor Outcomes of Older Adults with Acute Promyelocytic Leukemia (APL) Regardless of Insurance Types

Prajwal Dhakal, Elizabeth R. Lyden, Utsav Joshi, Avantika Pyakuryal, Krishna Gundabolu, Vijaya R. Bhatt

Blood (2021) 138 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2021-150896

Published: 2021

Journal Articles

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Krishna Gundabolu, Vijaya R. Bhatt, Lynette M. Smith, Valerie K Shostrom, Lori J. Maness, Zaid S. Al-Kadhimi, Julie M. Vose, R. Gregory Bociek, Matthew A. Lunning, Avyakta Kallam, Christopher D'Angelo, Muhamed Baljevic, Apar K Ganti

Blood (2021) 138 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2021-148945

Published: 2021

Journal Articles

Five-Year Outcomes of Chronic Red Blood Cell Exchange Transfusion Program for Patients with Sickle Cell Disease, the Experience of University of Nebraska Medical Center

Omar Abughanimeh, Steven Ebers, Mahammed Khan Suheb, Julie Eclov, Robin High, Aleh Bobr, Scott A Koepsell, James Harper, Krishna Gundabolu, Alex Nester, Laxmi Narayana Buddharaju

Blood (2021) 138 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2021-146718

Published: 2021

Journal Articles

Association of Insurance Types and Survival in Acute Promyelocytic Leukemia (APL)

Prajwal Dhakal, Elizabeth R. Lyden, Utsav Joshi, Avantika Pyakuryal, Krishna Gundabolu, Vijaya R. Bhatt

Blood (2021) 138 (Supplement 1): 4129.

https://doi.org/10.1182/blood-2021-151055

Published: 2021

Journal Articles

Retroperitoneal hemorrhage following a bone marrow biopsy

Krishna Gundabolu, Roberto Silva Aguiar

Blood (2021) 138 (14): 1283.

https://doi.org/10.1182/blood.2021011319

Published: 2021

Journal Articles

Age-Based Probability of Ten-Year Overall Survival (OS) of Acute Myeloid Leukemia (AML): A National Cancer Database (NCDB) Analysis

Vijaya R. Bhatt, MD, Valerie K Shostrom, Nabin Khanal, MBBS, Chakra P Chaulagain, MD, Fiona He, MD, Krishna Gundabolu, MBBS

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134434

Published: 2020

NARROW

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis

Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State

Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT

Averting a terminal transplant cascade

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Use of Geriatric Assessment and Genetic Profiling to Personalize Selection of Intensive Versus Low Intensity Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML): Final Results of a Phase II Trial

Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies

Novel First-in-Class Drug ONC201 As a Post-Transplant Maintenance for AML and MDS: A Phase I Trial in Progress

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial

Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients’ Function and Health-Related Quality of Life Change with Treatment?

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Outcomes of Patients with Budd-Chiari Syndrome and Factors Predicting the Need for TIPS & Liver Transplantation - a Single-Center Long-Term Experience

Poor Outcomes of Older Adults with Acute Promyelocytic Leukemia (APL) Regardless of Insurance Types

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Five-Year Outcomes of Chronic Red Blood Cell Exchange Transfusion Program for Patients with Sickle Cell Disease, the Experience of University of Nebraska Medical Center

Association of Insurance Types and Survival in Acute Promyelocytic Leukemia (APL)

Retroperitoneal hemorrhage following a bone marrow biopsy

Age-Based Probability of Ten-Year Overall Survival (OS) of Acute Myeloid Leukemia (AML): A National Cancer Database (NCDB) Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only